| Literature DB >> 34410348 |
Megan A Dunay1,2, Sarah L McClain3, Rick L Holloway1, Sarah L W Norris4, Talie Bendixsen Randall1, Caitlin E Mohr3, Brent H Sasaki3, Joseph A Coones3, Nicholas J Vietri3.
Abstract
Completion of a 5-day course of remdesivir was associated with approximately 17-fold increased odds of survival among a sample of 54 nursing home residents with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection during the course of an outbreak from October to December 2020. Remdesivir was well tolerated; administration was logistically feasible in a pre-hospital environment. Published by Oxford University Press for the Infectious Diseases Society of America 2021.Entities:
Keywords: COVID-19; LTCF; SARS-CoV-2; SNF; remdesivir
Mesh：
Substances：
Year: 2022 PMID： 34410348 PMCID： PMC8499795 DOI： 10.1093/cid/ciab715
Source DB: PubMed Journal: Clin Infect Dis ISSN： 1058-4838 Impact factor: 9.079